Literature DB >> 8290606

Genetic heterogeneity of hepatocellular carcinoma.

H Unsal1, C Yakicier, C Marçais, M Kew, M Volkmann, H Zentgraf, K J Isselbacher, M Ozturk.   

Abstract

We studied 80 hepatocellular carcinomas from three continents for p53 gene (TP53) mutations and hepatitis B virus (HBV) sequences. p53 mutations were frequent in tumors from Mozambique but not in tumors from South Africa, China, and Germany. Independent of geographic origin, most tumors were positive for HBV sequences. X gene coding sequences of HBV were detected in 78% of tumors, whereas viral sequences in the surface antigen- and core antigen-encoding regions were present in less than 45% of tumors. These observations indicate that hepatocellular carcinomas are genetically heterogeneous. Mozambican-type of hepatocellular carcinomas are characterized by a high incidence of p53 mutations related to aflatoxins. In other tumors, the rarity of p53 mutations combined with the frequent presence of viral X gene coding sequences suggests a possible interference of HBV with the wild-type p53 function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8290606      PMCID: PMC43041          DOI: 10.1073/pnas.91.2.822

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

Authors:  D P Aden; A Fogel; S Plotkin; I Damjanov; B B Knowles
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

2.  Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen.

Authors:  P Paterlini; G Gerken; E Nakajima; S Terre; A D'Errico; W Grigioni; B Nalpas; D Franco; J Wands; M Kew
Journal:  N Engl J Med       Date:  1990-07-12       Impact factor: 91.245

3.  p53 gene mutation spectrum in hepatocellular carcinoma.

Authors:  T Oda; H Tsuda; A Scarpa; M Sakamoto; S Hirohashi
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

4.  Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain.

Authors:  C Challen; J Lunec; W Warren; J Collier; M F Bassendine
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

5.  Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas.

Authors:  S Hosono; M J Chou; C S Lee; C Shih
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

6.  Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; H Kokuryu; J Toguchida; D W Yandell; M Ikenega; H Imura; K Ishizaki
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

7.  Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma.

Authors:  M A Feitelson; M Zhu; L X Duan; W T London
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

Review 8.  The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma.

Authors:  S Sell
Journal:  Int J Dev Biol       Date:  1993-03       Impact factor: 2.203

9.  Aberrations of p53 gene in human hepatocellular carcinoma from China.

Authors:  D Li; Y Cao; L He; N J Wang; J R Gu
Journal:  Carcinogenesis       Date:  1993-02       Impact factor: 4.944

Review 10.  The multistep nature of cancer.

Authors:  B Vogelstein; K W Kinzler
Journal:  Trends Genet       Date:  1993-04       Impact factor: 11.639

View more
  37 in total

1.  HBx-DNA probe preparation and its application in study of hepatocarcinogenesis.

Authors:  Feng-Guang Gao; Wen-Sheng Sun; Ying-Lin Cao; Li-Ning Zhang; Jing Song; Hua-Fen Li; Shi-Kun Yan
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

2.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

Review 3.  Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma.

Authors:  Leilei Chen; Tim Hon Man Chan; Xin-yuan Guan
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

Review 4.  Hepatic neoplasia: reflections and ruminations.

Authors:  K Aterman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.

Authors:  Ju Dong Yang; Sean F Altekruse; Mindie H Nguyen; Gregory J Gores; Lewis R Roberts
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

Review 6.  Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis.

Authors:  Yi Tian; Weibing Yang; Jianxun Song; Yuzhang Wu; Bing Ni
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

7.  Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.

Authors:  Cem Cengiz; Ulus S Akarca; Erdem Goker; Gul Yuce
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 8.  Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis.

Authors:  Yasunobu Matsuda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

9.  Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Cheng-Yuan Hsia; Gar-Yang Chau; Wing-Yiu Lui; Yi-Hsiang Huang; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

10.  Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis.

Authors:  Y D Yoo; H Ueda; K Park; K C Flanders; Y I Lee; G Jay; S J Kim
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.